Quantcast

NxStage Announces Presentation of Data at the American Society of Nephrology’s Renal Week 2008 Annual Meeting

August 22, 2008

LAWRENCE, Mass., Aug. 22 /PRNewswire-FirstCall/ — NxStage Medical, Inc. , a leading manufacturer of innovative dialysis products, today announced that the interim quality of life analysis from the FREEDOM study will be presented during the American Society of Nephrology Renal Week 2008 Annual Meeting taking place November 4-9, 2008, in Philadelphia, Pennsylvania. An abstract entitled “Daily Home HD (DHD) Improves Quality of Life (QoL) Measures, Depressive Symptoms and Recovery Time: Interim Results from the FREEDOM Study,” is scheduled to be presented on Friday, November 7, 2008 at 4:00 p.m.

Sponsored by NxStage, and implemented in collaboration with up to 70 U.S. dialysis clinics and the United States Renal Data System (USRDS), FREEDOM (Following Rehabilitation, Economics, and Everyday Dialysis Outcome Measurements) is a prospective study to quantify the clinical benefits and cost savings of daily therapy administered to Medicare patients with the NxStage System One versus conventional thrice-weekly dialysis.

About NxStage Medical

NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company’s website at http://www.nxstage.com/.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words “anticipate,”"believe,”"expect,”"estimate,”"plan,” and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, any unanticipated delay in presenting the QoL data relating to the FREEDOM study and other factors that are discussed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact:    Kristen K. Sheppard, Esq.    VP, Investor Relations    ksheppard@nxstage.com  

NxStage Medical, Inc.

CONTACT: Kristen K. Sheppard, Esq., VP, Investor Relations,+1-978-332-5923, ksheppard@nxstage.com

Web site: http://www.nxstage.com/




comments powered by Disqus